Shilpa Medicare Limited (SHILPAMED) breaks out, gaining +5% to ₹605.0 on the NSE on 30 Jun 2026, backed by its expansion of partnership with Orion Corporation for Nivolumab biosimilar. This move comes as the stock cleared its 6M resistance trendline, signaling a breakout after approaching resistance for some time. Shilpa Medicare, a mid-cap player in the specialty and generic drug manufacturing sector, shows a company-specific catalyst driving today’s move, distinct from broader sector momentum.

Technical setup — trendlines & DMA

From a chart perspective, SHILPAMED is now trading well above its 6M support trendline, which ends at ₹467.42, representing a 22.74% gain from this level. The stock has also surpassed its 6M resistance trendline, ending at ₹590.83, by 2.34%, confirming the breakout. The 50-DMA at ₹484.4 is above the 200-DMA at ₹378.1, indicating a bullish trend. However, the stock is currently 18.41% above the 50-DMA, suggesting it might be in an extended phase. Within its 52W range of ₹259.5–₹598.9, the current price is in the upper third, reflecting strong performance but also implying that a substantial portion of the move might already be priced in.

Fundamentals & business context

With a PE of 46.0, Shilpa Medicare’s valuation appears stretched given its 15.8% profit margin and a 5-year revenue CAGR of 13.8%. This suggests the market might be pricing in expectations of future growth or a turnaround, despite the current profit CAGR showing no growth. The 10.6% institutional holding indicates a cautious approach from the smart money, possibly reflecting concerns over the company’s current growth trajectory and valuation. Today’s move is directly linked to the NSE catalyst of expanding the partnership for Nivolumab biosimilar, highlighting a strategic move that could impact future revenue streams.

Algorithmic scorecard

The overall scorecard reflects a technically strong but fundamentally weaker position for Shilpa Medicare. The strongest signals come from the bullish trend, with the 50-day average above the 200-day average, and the stock’s low volatility, indicated by a beta of 0.20, suggesting stability and less market risk. These factors point to a stock that, while currently in an extended phase, has shown resilience and consistent performance. On the weaker side, the negligible dividend yield of 0.09% offers little to no income for investors, and the inability to calculate a PEG ratio due to insufficient growth data raises questions about the sustainability of the current valuation. These elements suggest that while the technicals are strong, investors should be cautious about the fundamental underpinnings of the stock’s valuation.

Company outlook

Looking ahead, management has outlined an ambitious roadmap for FY27, highlighting several key initiatives and growth drivers. They expect approval for the third U.S. NCE program, steady growth in the API business, and good growth possibilities in the formulation division. The launch of Aflibercept and Nivolumab, along with the entry of two NBE programs into Phase I studies, are expected to contribute significantly to revenue. Additionally, the completion of supplies for an innovator program and the start of human studies for a second ADC biosimilar product are slated for FY27. The company also plans to commission new oncology and peptide manufacturing blocks, start human Phase I studies for two NBE programs, and submit an IMPD for a recombinant human albumin program. These initiatives, coupled with the expected healthy growth in the European business and revenue contribution from the CDMO business in biologics, paint a picture of a company poised for growth, albeit with execution risks associated with such a broad and ambitious plan.

Get all details on SHILPAMED — P&L, peers, shareholding and more on TradeAlone.